scholarly journals Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder

2018 ◽  
Vol 17 (2) ◽  
pp. e1352-e1353
Author(s):  
P.E. Van Kerrebroeck ◽  
S. De Wachter ◽  
A. Ruffion ◽  
F. Van Der Aa ◽  
M.-A. Perrouin-Verbe ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Prospective Study ◽  
Sacral Neuromodulation ◽  
A Prospective Study

scholarly journals Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder

2018 ◽  
Vol 37 (S2) ◽  
pp. S17-S22 ◽  
Author(s):  
Bertil Blok ◽  
Philip Van Kerrebroeck ◽  
Stefan de Wachter ◽  
Alain Ruffion ◽  
Frank Van der Aa ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Prospective Study ◽  
Sacral Neuromodulation ◽  
A Prospective Study

A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments

2017 ◽  
Vol 37 (1) ◽  
pp. 177-185 ◽  
Author(s):  
Suvapun Bunniran ◽  
Cralen Davis ◽  
Rita Kristy ◽  
Daniel Ng ◽  
Carol R. Schermer ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Prospective Study ◽  
Patient Reported Outcomes ◽  
Patient Reported ◽  
A Prospective Study

scholarly journals Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study

2017 ◽  
Vol 21 (1) ◽  
pp. 62-67 ◽  
Author(s):  
Volkan Solmaz ◽  
Sebahattin Albayrak ◽  
Arslan Tekatas ◽  
Dürdane Aksoy ◽  
Yusuf Gençten ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Prospective Study ◽  
A Prospective Study

scholarly journals The Efficacy and Safety of Uractiv Control in Overactive Bladder Treatment

2020 ◽  
Vol 71 (1) ◽  
pp. 390-394
Author(s):  
Calin Bogdan Chibelean ◽  
Veronica Ghirca ◽  
Razvan-Cosmin Petca ◽  
Daniel Porav-Hodade ◽  
Ioan Alin Nechifor-Boila ◽  
...  
Keyword(s):  
Placebo Group ◽  
Side Effects ◽  
Overactive Bladder ◽  
Prospective Study ◽  
Treatment Option ◽  
Alternative Treatment ◽  
Control Group ◽  
Efficacy And Safety ◽  
A Prospective Study ◽  
Safe Treatment Option

The aim of this study is to evaluate the efficacy and safety of Uractiv Control as an alternative treatment with no side effects in Overactive Bladder (OAB). We performed a prospective study over a period of 15 months (May 2018- September 2019) in Department of Urology from Targu-Mureș. We included 165 patients diagnosed with OAB wet (129 patients) and dry form (36 patients) which were fully evaluated over a 3-month period of treatment. 48 patients were treated with placebo 1 month and were evaluated by the same parameters like Uractiv Control group. The frequency of micturition during the day and night after the treatment with Uractiv Control was improved compared to placebo group (p=0.0001) and also the loss of urine episodes (p=0.03). Patients did not report any significant side effects of the treatment. Uractiv Control represents a safe treatment option with no side effects and improvement of the storage in OAB.

Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study

2019 ◽  
Vol 31 (12) ◽  
pp. 2653-2660 ◽  
Author(s):  
Shilpa Iyer ◽  
Svjetlana Lozo ◽  
Carolyn Botros ◽  
Chi Wang ◽  
Alexandra Warren ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Prospective Study ◽  
Cognitive Changes ◽  
Anticholinergic Medications ◽  
A Prospective Study

scholarly journals Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Farida van Rey ◽  
John Heesakkers
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Overactive Bladder ◽  
Prospective Study ◽  
Outcome Measure ◽  
Dose Increase ◽  
Neurogenic Disease ◽  
Multiple Sclerosis Patients ◽  
A Prospective Study ◽  
Disease Specific

Objective. To assess the efficacy and the effect on Qol of solifenacin for the treatment of OAB in MS patients.Patients and Methods. Thirty MS patients suffering from OAB were treated with solifenacin 5/10 mg for 8 weeks. The first 4 weeks patients received solifenacin 5 mg. At week 4 patients could request a dose increase to 10 mg. The efficacy was evaluated at 8 weeks.Results. After 4 weeks of treatment, 28 patients reported acceptable or no side effects. 17 continued the study with the 10 mg dosage, and 11 stayed on 5 mg solifenacin. Two patients withdrew from the study due to side effects. Solifenacin 5/10 mg for 8 weeks resulted in a significant decrease in number of micturitions and number of pads used per day compared to baseline. Also the severity of urgency prior to voiding decreased significantly, and an increase was seen in the volume per void. Twenty out of 30 patients chose to continue solifenacin therapy after termination of the study. The majority of patients reported global QoL improvement.Conclusions. Solifenacin is effective in the treatment of MS patients with OAB symptoms. This is the first study with solifenacin in a specific neurogenic patient group with a neurogenic disease-specific QoL outcome measure (MS-QoL 54).

Sign in / Sign up

Export Citation Format

Share Document